메뉴 건너뛰기




Volumn 107, Issue 1, 2012, Pages 155-164

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

Author keywords

Angiogenesis; Bevacizumab; Carboplatin; Glioblastoma; Irinotecan; Vascular endothelial growth factor

Indexed keywords

AMINOTRANSFERASE; BEVACIZUMAB; CARBAMAZEPINE; CARBOPLATIN; CORTICOSTEROID; CYTOCHROME P450 3A; IRINOTECAN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

EID: 84861312289     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0722-2     Document Type: Article
Times cited : (114)

References (54)
  • 1
    • 75449088610 scopus 로고    scopus 로고
    • FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme
    • Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14:1131-1138
    • (2009) Oncologist , vol.14 , pp. 1131-1138
    • Cohen, M.H.1    Shen, Y.L.2    Keegan, P.3    Pazdur, R.4
  • 2
    • 77951648711 scopus 로고    scopus 로고
    • Bevacizumab and recurrent malignant gliomas: A European perspective
    • doi:10.1200/JCO.2009.26.9027 author reply e190-182
    • Wick W, Weller M, van den Bent M, Stupp R (2010) Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 28:e188-e189. doi:10.1200/JCO.2009.26.9027 author reply e190-182
    • (2010) J Clin Oncol , vol.28
    • Wick, W.1    Weller, M.2    Van Den Bent, M.3    Stupp, R.4
  • 5
    • 4344594951 scopus 로고    scopus 로고
    • Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis
    • Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-oncol 6:227-235
    • (2004) Neuro-oncol , vol.6 , pp. 227-235
    • Lamborn, K.R.1    Chang, S.M.2    Prados, M.D.3
  • 6
    • 34047238978 scopus 로고    scopus 로고
    • The relationship between sixmonth progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
    • Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA (2007) The relationship between sixmonth progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-oncology 9:29-38
    • (2007) Neuro-oncology , vol.9 , pp. 29-38
    • Ballman, K.V.1    Buckner, J.C.2    Brown, P.D.3    Giannini, C.4    Flynn, P.J.5    Laplant, B.R.6    Jaeckle, K.A.7
  • 8
    • 0026446102 scopus 로고
    • Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
    • Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848
    • (1992) Nature , vol.359 , pp. 845-848
    • Plate, K.H.1    Breier, G.2    Weich, H.A.3    Risau, W.4
  • 9
    • 0028174337 scopus 로고
    • Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
    • Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576-579
    • (1994) Nature , vol.367 , pp. 576-579
    • Millauer, B.1    Shawver, L.K.2    Plate, K.H.3    Risau, W.4    Ullrich, A.5
  • 10
    • 0034648765 scopus 로고    scopus 로고
    • Angiogenesis in cancer and other diseases
    • Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
    • (2000) Nature , vol.407 , pp. 249-257
    • Carmeliet, P.1    Jain, R.K.2
  • 11
    • 0036842215 scopus 로고    scopus 로고
    • Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    • Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380
    • (2002) J Clin Oncol , vol.20 , pp. 4368-4380
    • Dvorak, H.F.1
  • 12
    • 11844254414 scopus 로고    scopus 로고
    • Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
    • Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
    • (2005) Science , vol.307 , pp. 58-62
    • Jain, R.K.1
  • 14
    • 2542628099 scopus 로고    scopus 로고
    • Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
    • Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736
    • (2004) Cancer Res , vol.64 , pp. 3731-3736
    • Tong, R.T.1    Boucher, Y.2    Kozin, S.V.3    Winkler, F.4    Hicklin, D.J.5    Jain, R.K.6
  • 16
    • 3042548695 scopus 로고    scopus 로고
    • Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts
    • Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35-52
    • (2004) Am J Pathol , vol.165 , pp. 35-52
    • Inai, T.1    Mancuso, M.2    Hashizume, H.3    Baffert, F.4    Haskell, A.5    Baluk, P.6    Hu-Lowe, D.D.7    Shalinsky, D.R.8    Thurston, G.9    Yancopoulos, G.D.10    McDonald, D.M.11
  • 22
    • 0020110252 scopus 로고
    • Interim analyses for randomized clinical trials: The group sequential approach
    • Pocock SJ (1982) Interim analyses for randomized clinical trials: the group sequential approach. Biometrics 38:153-162
    • (1982) Biometrics , vol.38 , pp. 153-162
    • Pocock, S.J.1
  • 26
    • 77954748580 scopus 로고    scopus 로고
    • Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial
    • doi:10.1093/neuonc/nop063
    • Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sorensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS (2010) Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 12:508-516. doi:10.1093/neuonc/nop063
    • (2010) Neuro-oncology , vol.12 , pp. 508-516
    • Hasselbalch, B.1    Lassen, U.2    Hansen, S.3    Holmberg, M.4    Sorensen, M.5    Kosteljanetz, M.6    Broholm, H.7    Stockhausen, M.T.8    Poulsen, H.S.9
  • 35
    • 0025811273 scopus 로고
    • Intravenous carboplatin for recurrent malignant glioma: A phase II study
    • Yung WK, Mechtler L, Gleason MJ (1991) Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9:860-864
    • (1991) J Clin Oncol , vol.9 , pp. 860-864
    • Yung, W.K.1    Mechtler, L.2    Gleason, M.J.3
  • 41
    • 0033761232 scopus 로고    scopus 로고
    • Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models
    • Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette CA, Tan M, Friedman HS, Brent TP (2000) Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 6:4110-4118
    • (2000) Clin Cancer Res , vol.6 , pp. 4110-4118
    • Houghton, P.J.1    Stewart, C.F.2    Cheshire, P.J.3    Richmond, L.B.4    Kirstein, M.N.5    Poquette, C.A.6    Tan, M.7    Friedman, H.S.8    Brent, T.P.9
  • 43
    • 34047260282 scopus 로고    scopus 로고
    • Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model
    • Jain RK, Tong RT, Munn LL (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67:2729-2735
    • (2007) Cancer Res , vol.67 , pp. 2729-2735
    • Jain, R.K.1    Tong, R.T.2    Munn, L.L.3
  • 45
    • 38349135709 scopus 로고    scopus 로고
    • Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization
    • doi:10.1158/1535-7163.MCT-07-0552
    • Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, Leenders WP (2008) Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 7:71-78. doi:10.1158/1535-7163.MCT-07-0552
    • (2008) Mol Cancer Ther , vol.7 , pp. 71-78
    • Claes, A.1    Wesseling, P.2    Jeuken, J.3    Maass, C.4    Heerschap, A.5    Leenders, W.P.6
  • 46
    • 0347378566 scopus 로고    scopus 로고
    • Invasion as limitation to anti-angiogenic glioma therapy
    • Lamszus K, Kunkel P, Westphal M (2003) Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 88: 169-177
    • (2003) Acta Neurochir Suppl , vol.88 , pp. 169-177
    • Lamszus, K.1    Kunkel, P.2    Westphal, M.3
  • 47
    • 0033822622 scopus 로고    scopus 로고
    • Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
    • Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314
    • (2000) Neoplasia , vol.2 , pp. 306-314
    • Rubenstein, J.L.1    Kim, J.2    Ozawa, T.3    Zhang, M.4    Westphal, M.5    Deen, D.F.6    Shuman, M.A.7
  • 50
    • 77952309402 scopus 로고    scopus 로고
    • Tumor invasion after treatment of glioblastoma with bevacizumab: Radiographic and pathologic correlation in humans and mice
    • doi:10.1093/neuonc/nop027
    • de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncology 12:233-242. doi:10.1093/neuonc/nop027
    • (2010) Neuro-oncology , vol.12 , pp. 233-242
    • De Groot, J.F.1    Fuller, G.2    Kumar, A.J.3    Piao, Y.4    Eterovic, K.5    Ji, Y.6    Conrad, C.A.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.